APOBEC3B expression in human leptomeninges and meningiomas

Johnson,Mahlon D.; Reeder,Jay E.; O'Connell,Mary

doi:10.3892/ol.2016.5377

APOBEC3B expression in human leptomeninges and meningiomas

Authors:
- Mahlon D. Johnson
- Jay E. Reeder
- Mary O'Connell
View Affiliations

Affiliations: Department of Pathology, Division of Neuropathology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14623, USA, Department of Urology, University of Rochester Medical Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14623, USA
Published online on: November 10, 2016 https://doi.org/10.3892/ol.2016.5377
Pages: 5344-5348

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nucleic acid-editing enzymes of the apolipoprotein B mRNA-editing enzyme (APOBEC) family have been associated with somatic mutation in cancer. However, the role of APOBEC catalytic subunit 3B (APOBEC3B) editing in the pathogenesis of base substitutions in meningiomas is unknown. In the present study, the expression of APOBEC3B was examined by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analyses in five fetal and one adult human leptomeninges and 38 meningiomas. Genomic DNA was sequenced using the Illumina Tru‑Seq Cancer Panel. Three meningioma primary cultures were also established and treated with cerebrospinal fluid form patients without neurological disease or platelet‑derived growth factor‑BB (PDGF‑BB), prior to evaluation of APOBEC3B expression. By western blotting, APOBEC3B was revealed to be present in 100% of the fetal leptomeninges, and in 88% of World Health Organization grade I, 100% of grade II and 83% of grade III meningiomas tested, but was not different between grades. RT‑qPCR revealed no difference in the mRNA expression of APOBEC3B between grades. Sequencing revealed no elevated levels of the C>T mutations that are characteristic of APOBEC3B editing of genomic DNA. Treatment with cerebrospinal fluid and PDGF‑BB had no effect on APOBEC3B protein expression in the leptomeningeal or meningioma cells. These findings suggest that the mutations associated with increased APOBEC3B expression may not be central to the pathogenesis of meningiomas.

View Figures

View References

1	Avesson L and Barry G: The emerging role of RNA and DNA editing in cancer. Biochim Biophys Acta. 1845:308–316. 2014.PubMed/NCBI
2	Kuong KJ and Loeb LA: APOBEC3B mutagenesis in cancer. Nat Genet. 45:964–965. 2013. View Article : Google Scholar : PubMed/NCBI
3	Benne R, Van den Burg J, Brakenhoff JP, Sloof P, Van Boom JH and Tromp MC: Major transcript of the frameshifted coxII gene from trypanosome mitochondria contains four nucleotides that are not encoded in the DNA. Cell. 46:819–826. 1986. View Article : Google Scholar : PubMed/NCBI
4	Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, et al: APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 494:366–370. 2013. View Article : Google Scholar : PubMed/NCBI
5	Burns MB, Temiz NA and Harris RS: Evidence for APOBEC3B in multiple human cancers. Nat Genet. 45:977–983. 2013. View Article : Google Scholar : PubMed/NCBI
6	Lada AG, Dhar A, Boissy RJ, Hirano M, Rubel AA, Rogozin IB and Pavlov YI: AID/APOBEC cytosine deaminase induces genome-wide kataegis. Biol Direct. 7:472012. View Article : Google Scholar : PubMed/NCBI
7	Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR and Neuberger MS: DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. ELife. 2:e005342013. View Article : Google Scholar : PubMed/NCBI
8	Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, et al: An APOBEC cytadine deaminase pattern is widespread in human cancers. Nat Genet. 45:970–976. 2013. View Article : Google Scholar : PubMed/NCBI
9	Okuyama S, Marusawa H, Matsumoto T, Ueda Y, Matsumoto Y, Endo Y, Takai A and Chiba T: Excessive activity of Apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis. Int J Cancer. 130:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
10	Jia P, Pao W and Zhao Z: Patterns and processes of somatic mutations in nine major cancers. BMC Med Genomics. 7:112014. View Article : Google Scholar : PubMed/NCBI
11	Goutagny S, Yang HW, Zuchman-Rossi J, Chan J, Dreyfuss JM, Park PJ, Black PM, Giovanni M, Carroll RS and Kalamarides M: Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res. 16:4155–4164. 2010. View Article : Google Scholar : PubMed/NCBI
12	Perry A, Louis DN, Scheithauer BW, Budka H and von Deimling A: MeningiomasTumours of the Nervous System. Louis DN, Ohgaki H, Wiestler OD and Cavenee WK: WHO Press; Geneva, Switzerland: pp. 164–172. 2007
13	Johnson MD, O'Connell M, Facik M, Maurer P, Jahromi B and Pilcher W: Cerebrospinal fluid stimulates leptomeningeal and meningioma cell proliferation and activation of STAT3. J Neurooncol. 107:121–131. 2012. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, et al: APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 73:7222–7231. 2013. View Article : Google Scholar : PubMed/NCBI
16	Sasaki H, Suzuki A, Tatematsu T, Shitara M, Hikosaka Y, Okuda K, Moriyama S, Yano M and Fujii Y: APOBEC3B gene overexpression in non-small-cell lung cancer. Biomed Rep. 2:392–395. 2014.PubMed/NCBI
17	Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, Kobayashi M, Kadowaki N and Takaori-Kondo A: APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep. 2:8062012. View Article : Google Scholar : PubMed/NCBI
18	Rebhandal S, Huemer M, Gassner FJ, Zaborsky N, Hebenstreit D, Catakovic K, Grössinger EM, Greil R and Geisberger R: APOBEC3 signature mutations in in chronic lymphocytic leukemia. Leukemia. 28:1929–1932. 2014. View Article : Google Scholar : PubMed/NCBI
19	Avesson L and Barry G: The emerging role of RNA and DNA editing in cancer. Biochim and Biophys Acta. 1845:308–316. 2014.